Avoiding cancer through collective behaviour - Nature Reviews Cancer In this Journal Club, Rodríguez-Lelis and Gómez-Schiavon discuss a study that challenges the oncogene-induced senescence paradigm and proposes that cooperative, feedback-driven growth arrest better explains growth dynamics in BRAF-mutant benign nevi.

#JournalClub🚨
Rodríguez-Lelis&Gómez-Schiavon @mgschiavon.bsky.social discuss a study that challenges the oncogene-induced senescence paradigm and proposes that cooperative, feedback-driven growth arrest better explains growth dynamics in #BRAF-mutant nevi.
#melanoma
👀

🔵 During Colorectal Cancer Awareness Month
Juisci is highlighting a dedicated space on #BRAF mutated #cancer (including #colorectal cancer research), developed in collaboration with #PierreFabre.

Do you want to learn more about #BRAF?

Join us now at our Lung Cancer Targeted Therapies OncTalk!

#LungCancer #TargetedTherapies #V600E #NSCLC #GRACE #LungCancerInformation

Now presenting Dr. Christina Baik:

"KRAS and BRAF mutated NSCLC".

#TargetedTherapies #LungCancer #GRACE #KRAS #NSCLC #BRAF

🔜 #ELCC26 @myesmo.bsky.social
🔥Don’t miss the target: BRAF, HER2, METex14 and EGFR exon20 in focus
☑️ #BRAF #HER2 #METex14 #EGFRex20ins
🎙️Chair: Dr. Caicun Zhou, Dr. Natasha Leighl
@oncoalert.bsky.social LARVOL #LCSM

Pfizer、BRAF V600E変異mCRCの一次治療でPFS改善：第3相BREAKWATERコホート3（BRAFTOVI＋ERBITUX＋FOLFIRI） | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野の最新情報を継続的に整理し、 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野の最新情報を継続的に整理し、

Pfizer's BREAKWATER Trial Cohort 3 Shows Significant PFS Improvement in First-Line BRAF V600E-Mutant mCRC

ファイザー、BRAF V600E変異mCRCの一次治療でPFS改善：第3相BREAKWATERコホート3（BRAFTOVI＋ERBITUX＋FOLFIRI）

stellanews.life/technology/8...

#ColorectalCancer #Pfizer #BREAKWATER #BRAF #Oncology #ClinicalTrial

Pfizer、BRAF V600E変異mCRCの一次治療でPFS改善：第3相BREAKWATERコホート3（BRAFTOVI＋ERBITUX＋FOLFIRI） | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野の最新情報を継続的に整理し、 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野の最新情報を継続的に整理し、

Pfizer's BREAKWATER Trial Cohort 3 Shows Significant PFS Improvement in First-Line BRAF V600E-Mutant mCRC

ファイザー、BRAF V600E変異mCRCの一次治療でPFS改善：第3相BREAKWATERコホート3（BRAFTOVI＋ERBITUX＋FOLFIRI）

stellanews.life/technology/8...

#ColorectalCancer #Pfizer #BREAKWATER #BRAF #Oncology #ClinicalTrial

Rewiring of oncogenic signaling in #DrugResistance is a moving target. In our new study, we used biophysical phosphoproteomics to investigate #BRAF mutant cancer, linking phosphorylation changes to protein function and #MolecularMechanisms through #Multi-Omics integration.
tinyurl.com/funsignaling

🫁 Most patients with #BRAF - mutant #NSCLC harbor a *non V600* alteration - a major therapeutic blind spot.

Here, we review the complex biology and therapeutic challenges for non-V600 #BRAF–driven #NSCLC

📑
authors.elsevier.com/a/1mTV35Xq2Q...

#BOLEROConsortium
@jtoonline.bsky.social

A New First-Line Option in BRAF-Mutant Metastatic CRC? The targeted duo of encorafenib and cetuximab plus FOLFIRI chemotherapy emerges as a potential first-line alternative to FOLFOX for patients with BRAF V600E-mutant metastatic colorectal cancer.

New hope in metastatic colorectal cancer! A targeted combo of encorafenib + cetuximab with FOLFIRI has shown higher response rates than chemo alone for #BRAF V600E‑mutant disease, offering a promising new option! www.medscape.com/viewarticle/... #colorectalcancer #targetedtherapy #Oncology #TCSC

#Review in #MedComm
#Melanoma: Pathogenesis and Targeted Therapy doi.org/10.1002/mco2...

This review summarizes the molecular classification of melanoma, synthesizes current therapeutic approaches, and highlights persistent clinical challenges.
#NRAS #BRAF #immunotherapy

Datenbank seltene BRAF-Mutationen: Heidelberg University Hospital Datenbank seltene BRAF-Mutationen

New tool maps rare #BRAF #melanoma mutations to outcomes. 130 patients, 23 variants & System Usability Score of 92.5. Data is open via R/Shiny, adaptable to other #RareCancers. Precision oncology just got smarter! www.klinikum.uni-heidelberg.de/en/hautklini...

#OncBluesky #PrecisionMedicine #CanSky

NEW: Development and Evaluation of a Web-Based Outcome Database for Advanced #Melanoma with Rare #BRAF #Mutations
www.thieme-connect.de/products/ejo...

#MedSky #CanSky #OncSky

Dr Kailyn FEI from #Chinese #Academy of #Medical #Sciences ( #CAMS )representing #Chinese society #Clinical #Oncology ( #CSCO ) looks at role for chemo #immunotherapy in rare mutant #NSCLC / #BRAF #ROS1 #RET / lots unpublished - not posted - data / #WIC2025 #SITC2025

#BRAF V600E–Mutant Diffuse Pulmonary #Langerhans Cell Histiocytosis Successfully Treated With #Dabrafenib Plus #Trametinib: A Case Report
onlinelibrary.wiley.com/doi/10.1002/...

BRAF-Mutant Colorectal Cancer Active and Recruiting Trials You Need to Know in 2025 - OncoDaily Explore active and recruiting trials in BRAFmutant metastatic colorectal cancer, highlighting novel therapies and strategies for better outcomes

BRAF-Mutant Colorectal Cancer Active and Recruiting Trials You Need to Know in 2025

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CRC #ColorectalCancer #BRAF

Point/counterpoint: Upfront BRAF inhibition for adult BRAF-mutant high-grade gliomas Gliomas classified as CNS WHO grade 3 and 4 (herein referred to as HGG) are aggressive, fast-growing tumors with a poor prognosis and limited therapeutic o

Happy to share our collaborative Point/Counterpoint article on upfront #BRAF inhibition for adult high-grade #gliomas - a summary of the first joint SNO/EANO Young Investigators debate at #SNO2024. @marjoleingeurts.bsky.social @mjlimfat.bsky.social doi.org/10.1093/neuo...

Glad to have the opportunity to be a panelist and learn from Chinese and international experts on the management of #BRAF #V600E mutant colorectal cancers

#CRC #HKSDO #CUHKmedicine

A blue kayak pulled up on shingle with a very calm sea beyond with people swimming in the sun

Making the most of the millpond which was Cardigan Bay at Aberystwyth tonight 😮. Barely a wave in sight... glorious 🥰

#Braf #BaeCeredigion 🌊🏊

2nd to last time I do this.

I hope. 😂🤞🏻

#melanoma #thankscancer #braf #cansky #oncosky #mentalhealth

New hope for BRAF V600E mCRC patients: BREAKWATER shows EC+mFOLFOX6 nearly doubles survival vs. standard chemo.
A potential new first-line standard for this high-risk population.
Link in comments 👇
#mCRC #BRAF #ClinicalTrials #oncology

Triple Therapy Regimen Significantly Improves Survival in BRAF V600E-Mutated Metastatic Colorectal Cancer - OncoDaily Triple Therapy Regimen Significantly Improves Survival in BRAF V600E-Mutated Metastatic Colorectal Cancer / American Society of Clinical Oncology, ASCO 2025,

Triple Therapy Regimen Significantly Improves Survival in BRAF V600E-Mutated Metastatic Colorectal Cancer
@mdanderson.bsky.social @ascocancer.bsky.social

oncodaily.com/insight/colo...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CRC #BRAF #LBA3500 #ASCO2025 #NEJM #GIOnc

BRAF mutations heighten melanoma risk—but research offers hope.💡On #MelanomaBRAFAwarenessDay, explore open-access findings on detection, treatment & outcomes via SciOpen. Follow the thread for key reads 👇 www.sciopen.com/journal/0965...
#SkinCancer #BRAF #SciOpen

Encorafenib + binimetinib shows strong efficacy, especially in treatment-naïve patients. Genomic-guided triplet therapies need refinement, resistance mechanisms are complex! 🧬

#Onco404 #Cancer #Kanser #Melanoma #TargetedTherapy #ClinicalTrials #BRAF #PrecisionMedicine #MedSky #OncSky

This phase II study assessed encorafenib + binimetinib (BRAFi/MEKi), followed by the addition of a third targeted agent based on genomic alterations at progression

@theaacr.bsky.social #CCR

#Onco404 #Cancer #Kanser #Melanoma #TargetedTherapy #ClinicalTrials #BRAF #PrecisionMedicine #MedSky #OncSky

#BRAF V600E detection and effective BRAF/MEKi treatment in a pure epithelioid #mesothelioma upon progression on ICI (biphasic MPM at baseline).

www.jtocrr.org/article/S266...

Giannis Mountzios: Shedding Light on Factors Influencing Treatment Sequence in BRAF Mutant NSCLC - OncoDaily Giannis Mountzios: Shedding Light on Factors Influencing Treatment Sequence in BRAF Mutant NSCLC / Albrecht Stenzinger, Ali Alaffas, Anna Kron, Anna Rasokat,

Shedding Light on Factors Influencing Treatment Sequence in BRAF Mutant NSCLC - Giannis Mountzios
@drgreeklungcancer.bsky.social

oncodaily.com/science/gian...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #BRAF

☑️ ctDNA positivity during monitoring predicted recurrence 5.9 months earlier than imaging.
☑️ #BRAF V600E/MSI-high tumors had <1% MRD+ rates and better outcomes.
☑️ #KRAS G12C mutations linked to 2.18x higher recurrence risk.

#Onco404 #Cancer #Kanser #CRC #MedSky #OncSky #MRD

This research could pave the way for clinical trials, potentially transforming outcomes for melanoma patients who progress on current therapies 🙌🎉

#Onco404 #Cancer #Oncology #Melanoma #BRAF #BRAFV600 #TargetedTherapy #Immunotherapy

✅ The combo showed activity in preclinical models, including immunotherapy-resistant xenografts.
✅ Dual targeting led to tumor regression and prolonged survival in mice, offering hope for relapsed patients ➡️🌟

#Onco404 #Cancer #Oncology #Melanoma #BRAF #BRAFV600 #TargetedTherapy #Immunotherapy